Although the recent phase II “GBM-Vax” trial shows no clinical efficacy of Audencel, as assessed through progression-free and overall survival of GBM patients, post-vaccination levels of CD8+ T cells in the blood were indicative of a significantly better survival among GBM patients (52). Here, CD8A is linked to glioblastoma.